Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956820 | 0.87 | SIGMAR1 (0.73) | DRD4SIGMAR1POLBSLC6A12L3MBTL1 | |
| SCHEMBL62237 | 0.81 | DRD4 (0.76) | DRD4SIGMAR1CXCR4TSHRSLC6A5 | |
| SCHEMBL6715536 | 0.80 | SLC6A5 (0.65) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL6715783 | 0.79 | SLC6A5 (0.64) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| SCHEMBL10251883 | 0.79 | CXCR4 (0.74) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| SCHEMBL27579051 | 0.78 | SIGMAR1 (0.74) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| SCHEMBL6714432 | 0.77 | SLC6A5 (0.57) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| SCHEMBL6712413 | 0.77 | CHRM2 (0.66) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| SCHEMBL30791189 | 0.76 | CXCR4 (1.00) | DRD4SIGMAR1CXCR4CHRM2CHRM1 | |
| Fumaric Acid SCHEMBL6713953 | 0.76 | SLC6A5 (0.59) | DRD4SIGMAR1CXCR4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1335912-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002042291-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | LIPC, CETP, MTTP | DRD4 2894/4885SIGMAR1 230/4885CXCR4 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.